The Immunotherapeutic Effect of SIRPα-Silenced DCs against Cervical Cancer

Table 1

Percentage of DCs expressing CD1a, CD80, CD83, CD86, and HLA-DR.

	CD1a	CD80	CD83	CD86	HLA-DR
Control
LPS	^a	^a	^a	^a	^a
Ad-shControl	^a	^a	^a	^a	^a
Ad-shSIRPα	^a,b	^a,b	^a,c	^a,c	^a,b

Immature DCs were stimulated by Ad-shSIRPα. Percent of DCs expressing CD1a, CD80, CD83, CD86, and HLA-DR was detected using flow cytometry before and after 24 h TNF-α stimulation and analyzed by one-way ANOVA. ^aSignificant differences compared with that of the DC control, ; ^bno significant differences compared with that of the LPS control, ; ^csignificant differences compared with that of the LPS control or Ad-shControl, .